Sagimet Biosciences (SGMT) Return on Capital Employed (2023 - 2026)

Sagimet Biosciences' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 45.62% for Q1 2026.

• On a quarterly basis, Return on Capital Employed changed N/A year-over-year to 45.62% in Q1 2026; TTM through Mar 2026 was 45.62%, a N/A change from a year earlier, with the FY2025 full-year figure at 42.69%, up 121.0% from the prior year.
• Return on Capital Employed improved to 45.62% in Q1 2026 per SGMT's latest filing, from 48.48% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 32.64% in Q4 2023 and bottomed at 51.97% in Q3 2025.
• The 4-year median for Return on Capital Employed is 48.48% (2025), against an average of 44.57%.
• Across the five-year window, Return on Capital Employed sank 75 bps in 2024 and slumped 1509 bps in 2025, its largest moves.
• Year by year, Return on Capital Employed stood at 32.64% in 2023, then decreased by 2 bps to 33.39% in 2024, then plunged by 45 bps to 48.48% in 2025, then climbed by 6 bps to 45.62% in 2026.
• Per Business Quant, the three latest SGMT Return on Capital Employed figures stand at 45.62% (Q1 2026), 48.48% (Q4 2025), and 51.97% (Q3 2025).